Eli Lilly & (LLY) Stock
Major US pharmaceutical company leading diabetes and obesity treatments. Here's the price, business snapshot, and what's worth knowing about Eli Lilly & in October 2026.
Eli Lilly and Company (LLY) is a major US pharmaceutical group with a broad portfolio spanning diabetes, oncology, immunology and neuroscience. With a market capitalisation around $756.8bn, Lilly is known for strong commercial medicines such as GLP-1 and dual-agonist therapies that have driven recent sales growth, alongside a diversified R&D pipeline. Investors should know Lilly combines steady cash-generating marketed products with growth from newer launches and late‑stage candidates, but faces typical sector risks: regulatory review, patent expiries, pricing scrutiny and competition. Financials can be resilient but are sensitive to trial outcomes and reimbursement decisions. As general information, this summary is educational not personal financial advice — returns are not guaranteed and values can fall as well as rise. Prospective investors should consider their objectives, time horizon and risk tolerance, and may wish to consult an authorised financial adviser before investing.
Why It’s Moving
Lilly’s Retatrutide Crushes Ozempic in Head-to-Head Trial Ahead of Critical Q3 Earnings
- Clinical trial results showed retatrutide delivered more than double the weight loss of Ozempic’s highest approved dose, with participants losing an average of 44 to 47 lbs compared to lower figures for the competitor.
- The positive data comes amid mixed sentiment, as some employers reconsider GLP-1 coverage and analyst estimates for earnings per share have collapsed by a third in the last month due to pricing pressures.
- Leadership changes were announced with Patrik Jonsson retiring after 36 years and Ilya Yuffa taking over global markets, signaling a strategic shift as the company scales for its next phase of growth.
Lilly’s Retatrutide Crushes Ozempic in Head-to-Head Trial Ahead of Critical Q3 Earnings
- Clinical trial results showed retatrutide delivered more than double the weight loss of Ozempic’s highest approved dose, with participants losing an average of 44 to 47 lbs compared to lower figures for the competitor.
- The positive data comes amid mixed sentiment, as some employers reconsider GLP-1 coverage and analyst estimates for earnings per share have collapsed by a third in the last month due to pricing pressures.
- Leadership changes were announced with Patrik Jonsson retiring after 36 years and Ilya Yuffa taking over global markets, signaling a strategic shift as the company scales for its next phase of growth.
Sixth Month Growth Performance
When is the next earnings date for Eli Lilly & Co (LLY)?
Eli Lilly and Company is scheduled to release its next earnings report on October 29, 2026. This upcoming disclosure will cover the results for the third quarter of fiscal year 2026. The specific time of day for this announcement has not yet been determined by the company.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Eli Lilly's stock, expecting its price to rise toward $1,135.21.
Financial Health
Eli Lilly is performing strongly with high profits, cash flow, and solid revenue generation.
Dividend
Eli Lilly's dividend yield of 0.5% is low, indicating limited income from dividends. If you invested $1000 you would be paid $6.46 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Pipeline-led growth
Late-stage candidates and recent product roll-outs can boost revenue, though outcomes and timelines are uncertain and can affect share performance.
Global commercial reach
A wide geographic footprint helps diversify sales, but reimbursement policies and pricing pressure vary by market and may impact returns.
R&D and innovation
Heavy R&D investment fuels long-term potential, while the opposite side of the coin is the cost and risk of trials and regulatory review.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
